J Korean Med Assoc.  2018 Jul;61(7):428-434. 10.5124/jkma.2018.61.7.428.

Effect of antispasmodic agents for the treatment of irritable bowel syndrome

• Lee SH
• Jee SR

• KMID: 2416413
• DOI: http://doi.org/10.5124/jkma.2018.61.7.428

Abstract

Antispasmodics are effective in reducing abdominal pain and controlling spasm. Irritable bowel syndrome (IBS) patients have characteristic key factors such as intestinal motility disorder and visceral hypersensitivity. So antispasmodics have been used in the treatment of IBS for decades. Mebeverine blocks intestinal peristalsis but are not significantly better than placebo. Alverine citrate combined with simethicone is effective treatment option in IBS. Otilonium and pinaverium bromide are poorly absorbed agents, so they have mostly local effect with minimal systemic adverse events. Phloroglucinol controls acute exacerbation of abdominal pain effectively. Tiropramide reduce abdominal discomfort without serious adverse events. Fenoverine control spasm in spastic colon but does not affect normal contraction. Trimebutine have dual actions that it inhibits hyperactive colon and activates hypomotile colon. Each drug has advantages and disadvantages. Antispasmodics are considered as the first treatment option of pain-dominant IBS.

Keyword

Parasympatholytics; Abdominal pain; Irritable bowel syndrome

MeSH Terms

Abdominal Pain
Citric Acid
Colon
Gastrointestinal Motility
Humans
Hypersensitivity
Irritable Bowel Syndrome*
Muscle Spasticity
Parasympatholytics*
Peristalsis
Phloroglucinol
Simethicone
Spasm
Trimebutine
Citric Acid
Parasympatholytics
Phloroglucinol
Simethicone
Trimebutine

Reference

1. Valenzuela J, Alvarado J, Cohen H, Damiao A, Francisconi C, Frugone L, Gonzalez JC, Hernandez A, Iade B, Itaqui Lopes MH, Latorre R, Prado J, Moraes-Filho P, Schmulson M, Soifer L, Valdovinos MA, Vesco E, Zalar A. Latin-American consensus document on irritable bowel syndrome. Gastroenterol Hepatol. 2004; 27:325–343.

2. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009; 104:Suppl 1. S1–S35.

3. Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver. 2011; 5:253–266.

4. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2005; (2):CD003460.

5. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther. 2006; 24:183–205.

6. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008; 337:a2313.

7. Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, Lim HC, Shin JE, Kim SE, Cho DH, Kim JH, Kim HJ. Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018; 24:197–215.

8. Annahazi A, Roka R, Rosztoczy A, Wittmann T. Role of anti-spasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014; 20:6031–6043.

9. Den Hertog A, Van den Akker J. Modification of alpha 1-receptor-operated channels by mebeverine in smooth muscle cells of guinea-pig taenia caeci. Eur J Pharmacol. 1987; 138:367–374.

10. Van Outryve M, Mayeur S, Meeus MA, Rosillon D, Hendrickx B, Ceuppens M. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther. 1995; 20:277–282.

11. Lu CL, Chen CY, Chang FY, Chang SS, Kang LJ, Lu RH, Lee SD. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000; 15:925–930.

12. Everitt H, Moss-Morris R, Sibelli A, Tapp L, Coleman N, Yardley L, Smith P, Little P. Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterol. 2013; 13:68.

13. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001; 15:355–361.

14. Coelho AM, Jacob L, Fioramonti J, Bueno L. Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype. J Pharm Pharmacol. 2001; 53:1419–1426.

15. Bueno L, Beaufrand C, Theodorou V, Andro-Delestrain MC. Influence of simethicone and alverine on stress-induced alterations of colonic permeability and sensitivity in rats: beneficial effect of their association. J Pharm Pharmacol. 2013; 65:567–573.

16. Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol Ther. 2002; 16:1187–1195.

17. Wittmann T, Paradowski L, Ducrotte P, Bueno L, Andro Delestrain MC. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010; 31:615–624.

18. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des. 2004; 10:3561–3568.

19. Evangelista S, Cochet P, Bromet N, Criscuoli M, Maggi CA. A distribution study with (14)C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab Dispos. 2000; 28:643–647.

20. Evangelista S, Giachetti A, Chapelain B, Neliat G, Maggi CA. Receptor binding profile of Otilonium bromide. Pharmacol Res. 1998; 38:111–117.

21. Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, Corazziari E, Badiali G, Pescatori M, Anastasio G. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol. 1991; 23:8 Suppl 1. 60–63.

22. Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, Naccarato R. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther. 1998; 12:1003–1010.

23. Clave P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J. OBIS Study Investigators. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011; 34:432–442.

24. Boeckxstaens G, Corazziari ES, Mearin F, Tack J. IBS and the role of otilonium bromide. Int J Colorectal Dis. 2013; 28:295–304.

25. Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011; 17:402–410.

26. Christen MM, Tassignon JP. Pinaverium bromide: a calcium channel blocker acting selectively on the gastrointestinal tract. Drug Dev Res. 1989; 18:101–112.

27. Malysz J, Farraway LA, Christen MO, Huizinga JD. Pinaverium acts as L-type calcium channel blocker on smooth muscle of colon. Can J Physiol Pharmacol. 1997; 75:969–975.

28. Lopez-Alvarenga JC, Sobrino-Cossío S, Remes-Troche JM, Chiu-Ugalde J, Vargas-Romero JA, Schmulson M. Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100mg plus simethicone 300mg po bid. Rev Gastroenterol Mex. 2013; 78:21–27.

29. Zheng L, Lai Y, Lu W, Li B, Fan H, Yan Z, Gong C, Wan X, Wu J, Huang D, Wang Y, Mei Y, Li Z, Jiang Z, Liu X, Ye J, Yang Y, Huang H, Xiao J. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clin Gastroenterol Hepatol. 2015; 13:1285–1292.

30. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology. 1997; 112:1714–1743.

31. Jafri W, Yakoob J, Hussain S, Jafri N, Islam M. Phloroglucinol in irritable bowel syndrome. J Pak Med Assoc. 2006; 56:5–8.

32. Chassany O, Bonaz B, Bruley DES Varannes S, Bueno L, Cargill G, Coffin B, Ducrotté P, Grange V. Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2007; 25:1115–1123.

33. Uruno T, Shirane M, Wada K, Tsunematsu R, Nagahamaya K, Matsuoka Y, Sunagane N, Kubota K. Possible mechanisms of action of the antispasmodic agent tiropramide in the isolated detrusor from rats. Jpn J Pharmacol. 1992; 60:275–280.

34. Park SH, Jang CH, Han JY, Choi MG, Choi GY, Chung IS, Chung KW, Sun HS, Kim BS. Double blind clinical trial of tiropramide in irritable bowel syndrome. Korean J Gastroenterol. 1993; 25:877–883.

35. Lee KN, Lee OY, Choi MG, Sohn CI, Huh KC, Park KS, Kwon JG, Kim N, Rhee PL, Myung SJ, Lee JS, Lee KJ, Park H, Lee YC, Choi SC, Jung HK, Jee SR, Choi CH, Kim GH, Park MI, Sung IK. Efficacy and safety of tiropramide in the treatment of patients with irritable bowel syndrome: a multicenter, randomized, double-blind, non-inferiority trial, compared with octylonium. J Neurogastroenterol Motil. 2014; 20:113–121.

36. De Santis D, Marrazzo R, Losasso C, Loffreda A, De Paola C, De Novellis V, Molinario L, Schiariti F, Marmo E. Phar-macodynamic profile of fenoverine, a novel modulator of smooth muscle motility. Drugs Exp Clin Res. 1989; 15:37–42.

37. Kim YT, Jung HC. Double-blind prospective controled study of fenoverine in irritablebowel syndrome. Korean J Gastroenterol. 1992; 24:263–267.

38. Kang SH, Jeen YT, Koo JS, Koo YS, Kim KO, Kim YS, Kim SY, Moon JS, Park JJ, Baek IH, Park SC, Lee SJ, Lee JH, Choung RS, Choi SC. Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study. Korean J Gastroenterol. 2013; 62:278–287.

39. Chariot P, Ratiney R, Le Maguet F, Fourestie V, Astier A, Gherardi R. Fenoverine-induced rhabdomyolysis. Hum Exp Toxicol. 1995; 14:654–656.

40. Frexinos J, Fioramonti J, Bueno L. Effect of trimebutine on colonic myoelectrical activity in IBS patients. Eur J Clin Pharmacol. 1985; 28:181–185.